{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T03:01:17Z","timestamp":1791860477724,"version":"4.3.4"},"reference-count":243,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2027,8,5]],"date-time":"2027-08-05T00:00:00Z","timestamp":1817424000000},"content-version":"am","delay-in-days":338,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Institutes of Health National Cancer Institute","doi-asserted-by":"publisher","award":["P30CA240139"],"award-info":[{"award-number":["P30CA240139"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cancertreatmentreviews.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Treatment Reviews"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.ctrv.2026.103197","type":"journal-article","created":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T15:42:39Z","timestamp":1785166959000},"page":"103197","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Chondrosarcoma: A comprehensive review of tumor biology, clinical behavior, and therapeutic advances"],"prefix":"10.1016","volume":"149","author":[{"given":"Luyuan","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Genevieve","family":"Bertolet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josiane E.","family":"Eid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William D.","family":"Tap","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew J.","family":"Wagner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony P.","family":"Conley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francis J.","family":"Hornicek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenfeng","family":"Duan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emanuela","family":"Palmerini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan C.","family":"Trent","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ctrv.2026.103197_bb0005","doi-asserted-by":"crossref","DOI":"10.12688\/f1000research.15953.1","article-title":"Chondrosarcoma: biology, genetics, and epigenetics","volume":"7","author":"Chow","year":"2018","journal-title":"F1000Res"},{"key":"10.1016\/j.ctrv.2026.103197_bb0010","series-title":"Sarcomas\u202f: Evidence-based diagnosis and management","first-page":"1","author":"Trent","year":"2020"},{"key":"10.1016\/j.ctrv.2026.103197_bb0015","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1002\/1097-0142(19950101)75:1+<203::AID-CNCR2820751308>3.0.CO;2-V","article-title":"Bone cancers","volume":"75","author":"Dorfman","year":"1995","journal-title":"Cancer"},{"key":"10.1016\/j.ctrv.2026.103197_bb0020","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.2106\/JBJS.H.00416","article-title":"Chondrosarcoma in the United States (1973 to 2003): an analysis of 2890 cases from the SEER database","volume":"91","author":"Giuffrida","year":"2009","journal-title":"J Bone Joint Surg Am"},{"key":"10.1016\/j.ctrv.2026.103197_bb0025","first-page":"1127","article-title":"Bone cancer incidence by morphological subtype: a global assessment","volume":"26","author":"Valery","year":"2015","journal-title":"Cancer Causes Control"},{"key":"10.1016\/j.ctrv.2026.103197_bb0030","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1097\/BLO.0b013e318059b8c9","article-title":"Osteosarcoma, chondrosarcoma, and Ewing\u2019s sarcoma: National Cancer Data Base Report","volume":"459","author":"Damron","year":"2007","journal-title":"Clin Orthop Relat Res"},{"key":"10.1016\/j.ctrv.2026.103197_bb0035","doi-asserted-by":"crossref","first-page":"608","DOI":"10.5435\/00124635-201010000-00004","article-title":"Secondary chondrosarcoma","volume":"18","author":"Lin","year":"2010","journal-title":"J Am Acad Orthop Surg"},{"key":"10.1016\/j.ctrv.2026.103197_bb0040","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13102390","article-title":"Chondrosarcoma-from molecular pathology to novel therapies","volume":"13","author":"Zajac","year":"2021","journal-title":"Cancers (Basel)."},{"key":"10.1016\/j.ctrv.2026.103197_bb0045","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/s11523-024-01115-3","article-title":"IDH1\/2 mutations in cancer: unifying insights and unlocking therapeutic potential for chondrosarcoma","volume":"20","author":"Deshmukh","year":"2024","journal-title":"Target Oncol"},{"key":"10.1016\/j.ctrv.2026.103197_bb0050","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1097\/BLO.0b013e3180f62608","article-title":"Does length of symptoms before diagnosis of sarcoma affect patient survival?","volume":"462","author":"Rougraff","year":"2007","journal-title":"Clin Orthop Relat Res"},{"key":"10.1016\/j.ctrv.2026.103197_bb0055","doi-asserted-by":"crossref","DOI":"10.3390\/jcm12072506","article-title":"Chondrosarcoma: a clinical review","volume":"12","author":"Gazendam","year":"2023","journal-title":"J Clin Med"},{"key":"10.1016\/j.ctrv.2026.103197_bb0060","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1007\/s00264-015-2706-x","article-title":"Management and prognostic significance of pathological fractures through chondrosarcoma of the femur","volume":"39","author":"Albergo","year":"2015","journal-title":"Int Orthop"},{"key":"10.1016\/j.ctrv.2026.103197_bb0065","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1002\/1097-0142(20010401)91:7<1201::AID-CNCR1120>3.0.CO;2-W","article-title":"Prognostic factors and outcome of pelvic, sacral, and spinal chondrosarcomas: a center-based study of 69 cases","volume":"91","author":"Bergh","year":"2001","journal-title":"Cancer"},{"key":"10.1016\/j.ctrv.2026.103197_bb0070","doi-asserted-by":"crossref","first-page":"605","DOI":"10.47162\/RJME.62.2.30","article-title":"Conventional grade 1 chondrosarcoma: a challenging diagnosis with important implications on therapy and prognosis","volume":"62","author":"Cozma","year":"2021","journal-title":"Rom J Morphol Embryol"},{"key":"10.1016\/j.ctrv.2026.103197_bb0075","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1148\/rg.235035134","article-title":"From the archives of the AFIP: imaging of primary chondrosarcoma: radiologic-pathologic correlation","volume":"23","author":"Murphey","year":"2003","journal-title":"Radiographics"},{"key":"10.1016\/j.ctrv.2026.103197_bb0080","doi-asserted-by":"crossref","first-page":"2194","DOI":"10.1002\/cam4.1146","article-title":"Digital PCR analysis of circulating tumor DNA: a biomarker for chondrosarcoma diagnosis, prognostication, and residual disease detection","volume":"6","author":"Gutteridge","year":"2017","journal-title":"Cancer Med"},{"key":"10.1016\/j.ctrv.2026.103197_bb0085","doi-asserted-by":"crossref","first-page":"Ra177","DOI":"10.12659\/MSM.881893","article-title":"Review of therapeutic strategies for osteosarcoma, chondrosarcoma, and Ewing\u2019s sarcoma","volume":"17","author":"Dai","year":"2011","journal-title":"Med Sci Monit"},{"key":"10.1016\/j.ctrv.2026.103197_bb0090","doi-asserted-by":"crossref","first-page":"637","DOI":"10.2217\/fon-2016-0226","article-title":"Novel therapeutic approaches in chondrosarcoma","volume":"13","author":"Polychronidou","year":"2017","journal-title":"Future Oncol"},{"key":"10.1016\/j.ctrv.2026.103197_bb0095","doi-asserted-by":"crossref","DOI":"10.3390\/ijms19010311","article-title":"Chondrosarcoma: a rare misfortune in aging human cartilage? The role of stem and progenitor cells in proliferation, malignant degeneration and therapeutic resistance","volume":"19","author":"Boehme","year":"2018","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.ctrv.2026.103197_bb0100","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1002\/jso.23173","article-title":"Clinical outcome of central conventional chondrosarcoma","volume":"106","author":"Angelini","year":"2012","journal-title":"J Surg Oncol"},{"key":"10.1016\/j.ctrv.2026.103197_bb0105","doi-asserted-by":"crossref","DOI":"10.1155\/2015\/623746","article-title":"The identification of prognostic factors and survival statistics of conventional central chondrosarcoma","volume":"2015","author":"Nota","year":"2015","journal-title":"Sarcoma"},{"key":"10.1016\/j.ctrv.2026.103197_bb0110","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1007\/s00256-012-1521-3","article-title":"The imaging of cartilaginous bone tumours. II Chondrosarcoma","volume":"42","author":"Douis","year":"2013","journal-title":"Skeletal Radiol"},{"key":"10.1016\/j.ctrv.2026.103197_bb0115","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1097\/01.blo.0000069888.31220.2b","article-title":"Secondary chondrosarcoma in osteochondroma: report of 107 patients","author":"Ahmed","year":"2003","journal-title":"Clin Orthop Relat Res"},{"key":"10.1016\/j.ctrv.2026.103197_bb0120","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1186\/s13023-022-02210-2","article-title":"Secondary peripheral chondrosarcoma arising in solitary osteochondroma: variables influencing prognosis and survival","volume":"17","author":"Righi","year":"2022","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.ctrv.2026.103197_bb0125","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1111\/his.12666","article-title":"Periosteal chondrosarcoma: a histopathological and molecular analysis of a rare chondrosarcoma subtype","volume":"67","author":"Cleven","year":"2015","journal-title":"Histopathology"},{"key":"10.1016\/j.ctrv.2026.103197_bb0130","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1002\/jor.24463","article-title":"Survival and prognosis of chondrosarcoma subtypes: SEER database analysis","volume":"38","author":"Amer","year":"2020","journal-title":"J Orthop Res"},{"key":"10.1016\/j.ctrv.2026.103197_bb0135","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1634\/theoncologist.2007-0237","article-title":"The clinical approach towards chondrosarcoma","volume":"13","author":"Gelderblom","year":"2008","journal-title":"Oncologist"},{"key":"10.1016\/j.ctrv.2026.103197_bb0140","doi-asserted-by":"crossref","first-page":"553","DOI":"10.5435\/JAAOS-D-20-01188","article-title":"Chondrosarcoma","volume":"29","author":"Weinschenk","year":"2021","journal-title":"J Am Acad Orthop Surg"},{"key":"10.1016\/j.ctrv.2026.103197_bb0145","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1038\/s41379-022-01008-8","article-title":"Dedifferentiated chondrosarcoma with minimal or small dedifferentiated component","volume":"35","author":"Dehner","year":"2022","journal-title":"Mod Pathol"},{"key":"10.1016\/j.ctrv.2026.103197_bb0150","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1002\/jso.24650","article-title":"Dedifferentiated chondrosarcoma: a survival analysis of 159 cases from the SEER database (2001\u22122011)","volume":"116","author":"Strotman","year":"2017","journal-title":"J Surg Oncol"},{"key":"10.1016\/j.ctrv.2026.103197_bb0155","article-title":"Classification of chondrosarcoma: from characteristic to challenging imaging findings","volume":"15","author":"Kim","year":"2023","journal-title":"Cancers (Basel)."},{"key":"10.1016\/j.ctrv.2026.103197_bb0160","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1053\/j.semdp.2014.01.006","article-title":"Cartilage-forming tumors","volume":"31","author":"Qasem","year":"2014","journal-title":"Semin Diagn Pathol"},{"key":"10.1016\/j.ctrv.2026.103197_bb0165","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1111\/j.1440-1827.2010.02530.x","article-title":"Matrix biochemistry and cell biology of dedifferentiated chondrosarcomas","volume":"60","author":"Dornauer","year":"2010","journal-title":"Pathol Int"},{"key":"10.1016\/j.ctrv.2026.103197_bb0170","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1046\/j.1365-2559.1998.00456.x","article-title":"De-differentiated chondrosarcoma is not a \u2018de-differentiated\u2019 chondrosarcoma","volume":"33","author":"Aigner","year":"1998","journal-title":"Histopathology"},{"key":"10.1016\/j.ctrv.2026.103197_bb0175","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1016\/0046-8177(95)90166-3","article-title":"p53 expression and DNA ploidy of cartilage lesions","volume":"26","author":"Coughlan","year":"1995","journal-title":"Hum Pathol"},{"key":"10.1016\/j.ctrv.2026.103197_bb0180","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1002\/(SICI)1096-9896(199912)189:4<454::AID-PATH467>3.0.CO;2-N","article-title":"Molecular genetic characterization of both components of a dedifferentiated chondrosarcoma, with implications for its histogenesis","volume":"189","author":"Bov\u00e9e","year":"1999","journal-title":"J Pathol"},{"key":"10.1016\/j.ctrv.2026.103197_bb0185","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1007\/s004280050478","article-title":"Mutation of p53 with loss of heterozygosity in the osteosarcomatous component of a dedifferentiated chondrosarcoma","volume":"436","author":"Grote","year":"2000","journal-title":"Virchows Arch"},{"key":"10.1016\/j.ctrv.2026.103197_bb0190","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1078\/0344-0338-00443","article-title":"Genetic and epigenetic alterations in tumor progression in a dedifferentiated chondrosarcoma","volume":"199","author":"R\u00f6pke","year":"2003","journal-title":"Pathol Res Pract"},{"key":"10.1016\/j.ctrv.2026.103197_bb0195","doi-asserted-by":"crossref","first-page":"2060","DOI":"10.1016\/j.ejca.2007.06.016","article-title":"Dedifferentiated chondrosarcoma: prognostic factors and outcome from a European group","volume":"43","author":"Grimer","year":"2007","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ctrv.2026.103197_bb0200","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1002\/path.2913","article-title":"IDH1 and IDH2 mutations are frequent events in central chondrosarcoma and central and periosteal chondromas but not in other mesenchymal tumours","volume":"224","author":"Amary","year":"2011","journal-title":"J Pathol"},{"key":"10.1016\/j.ctrv.2026.103197_bb0205","doi-asserted-by":"crossref","DOI":"10.1155\/2011\/405437","article-title":"Chondrosarcoma: with updates on molecular genetics","volume":"2011","author":"Kim","year":"2011","journal-title":"Sarcoma"},{"key":"10.1016\/j.ctrv.2026.103197_bb0210","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.mpdhp.2014.03.001","article-title":"Histologic variants of chondrosarcoma","volume":"20","author":"Chebib","year":"2014","journal-title":"Diagn Histopathol"},{"key":"10.1016\/j.ctrv.2026.103197_bb0215","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1038\/modpathol.2014.155","article-title":"NY-ESO-1 (CTAG1B) expression in mesenchymal tumors","volume":"28","author":"Endo","year":"2015","journal-title":"Mod Pathol"},{"key":"10.1016\/j.ctrv.2026.103197_bb0220","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.prp.2008.12.008","article-title":"Heterogeneity of angiogenesis and blood vessel maturation in cartilage tumors","volume":"205","author":"Kalinski","year":"2009","journal-title":"Pathol Res Pract"},{"key":"10.1016\/j.ctrv.2026.103197_bb0225","doi-asserted-by":"crossref","first-page":"2916","DOI":"10.1093\/annonc\/mdt374","article-title":"Advanced chondrosarcomas: role of chemotherapy and survival","volume":"24","author":"Italiano","year":"2013","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2026.103197_bb0230","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1302\/0301-620X.82B1.0820055","article-title":"Experience in the treatment of dedifferentiated chondrosarcoma","volume":"82","author":"Mitchell","year":"2000","journal-title":"J Bone Joint Surg Br"},{"key":"10.1016\/j.ctrv.2026.103197_bb0235","doi-asserted-by":"crossref","first-page":"2412","DOI":"10.2106\/00004623-200411000-00008","article-title":"Dedifferentiated chondrosarcoma: the role of chemotherapy with updated outcomes","volume":"86","author":"Dickey","year":"2004","journal-title":"J Bone Joint Surg Am"},{"key":"10.1016\/j.ctrv.2026.103197_bb0240","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/2045-3329-4-11","article-title":"Comprehensive analysis of published studies involving systemic treatment for chondrosarcoma of bone between 2000 and 2013","volume":"4","author":"van Maldegem","year":"2014","journal-title":"Clin Sarcoma Res."},{"key":"10.1016\/j.ctrv.2026.103197_bb0245","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1038\/modpathol.2016.108","article-title":"Analysis of PD-L1, T-cell infiltrate and HLA expression in chondrosarcoma indicates potential for response to immunotherapy specifically in the dedifferentiated subtype","volume":"29","author":"Kostine","year":"2016","journal-title":"Mod Pathol"},{"key":"10.1016\/j.ctrv.2026.103197_bb0250","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.ejca.2021.04.017","article-title":"Outcome in dedifferentiated chondrosarcoma for patients treated with multimodal therapy: results from the EUROpean bone over 40 sarcoma study","volume":"151","author":"Hompland","year":"2021","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ctrv.2026.103197_bb0255","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbo.2019.100221","article-title":"Advances in immune checkpoint inhibitors for bone sarcoma therapy","volume":"15","author":"Thanindratarn","year":"2019","journal-title":"J Bone Oncol."},{"key":"10.1016\/j.ctrv.2026.103197_bb0260","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15184581","article-title":"Mesenchymal chondrosarcoma from diagnosis to clinical trials","volume":"15","author":"Dudzisz-\u015aled\u017a","year":"2023","journal-title":"Cancers (Basel)."},{"key":"10.1016\/j.ctrv.2026.103197_bb0265","doi-asserted-by":"crossref","first-page":"2424","DOI":"10.1002\/cncr.23457","article-title":"Mesenchymal chondrosarcoma of soft tissues and bone in children, adolescents, and young adults: experiences of the CWS and COSS study groups","volume":"112","author":"Dantonello","year":"2008","journal-title":"Cancer"},{"key":"10.1016\/j.ctrv.2026.103197_bb0270","series-title":"Soft tissue and bone Tumours","author":"WHO Classification of Tumours Editorial Board","year":"2020"},{"key":"10.1016\/j.ctrv.2026.103197_bb0275","doi-asserted-by":"crossref","first-page":"61","DOI":"10.5858\/arpa.2010-0362-OA","article-title":"Mesenchymal chondrosarcoma: clinicopathologic study of 20 cases","volume":"136","author":"Shakked","year":"2012","journal-title":"Arch Pathol Lab Med"},{"key":"10.1016\/j.ctrv.2026.103197_bb0280","doi-asserted-by":"crossref","DOI":"10.1016\/j.prp.2022.153803","article-title":"A mesenchymal chondrosarcoma with aberrant nuclear expression of STAT6: a potential diagnostic pitfall","volume":"232","author":"Broggi","year":"2022","journal-title":"Pathol Res Pract"},{"key":"10.1016\/j.ctrv.2026.103197_bb0285","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1002\/gcc.20937","article-title":"Identification of a novel, recurrent HEY1-NCOA2 fusion in mesenchymal chondrosarcoma based on a genome-wide screen of exon-level expression data","volume":"51","author":"Wang","year":"2012","journal-title":"Genes Chromosomes Cancer"},{"key":"10.1016\/j.ctrv.2026.103197_bb0290","doi-asserted-by":"crossref","first-page":"40","DOI":"10.3892\/or.2014.3180","article-title":"Chromosome aberrations and HEY1-NCOA2 fusion gene in a mesenchymal chondrosarcoma","volume":"32","author":"Panagopoulos","year":"2014","journal-title":"Oncol Rep"},{"key":"10.1016\/j.ctrv.2026.103197_bb0295","doi-asserted-by":"crossref","first-page":"e55","DOI":"10.1111\/ped.12407","article-title":"Mesenchymal chondrosarcoma diagnosed on FISH for HEY1-NCOA2 fusion gene","volume":"56","author":"Moriya","year":"2014","journal-title":"Pediatr Int"},{"key":"10.1016\/j.ctrv.2026.103197_bb0300","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.humpath.2018.03.014","article-title":"Minute mesenchymal chondrosarcoma within osteochondroma: an unexpected diagnosis confirmed by HEY1-NCOA2 fusion","volume":"81","author":"Toki","year":"2018","journal-title":"Hum Pathol"},{"key":"10.1016\/j.ctrv.2026.103197_bb0305","doi-asserted-by":"crossref","first-page":"47","DOI":"10.2176\/nmccrj.cr.2019-0123","article-title":"Intracranial Mesenchymal chondrosarcoma lacking the typical histopathological features diagnosed by HEY1-NCOA2 gene fusion","volume":"7","author":"Uneda","year":"2020","journal-title":"NMC Case Rep J"},{"key":"10.1016\/j.ctrv.2026.103197_bb0310","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0049705","article-title":"Whole-transcriptome sequencing identifies novel IRF2BP2-CDX1 fusion gene brought about by translocation t(1;5)(q42;q32) in mesenchymal chondrosarcoma","volume":"7","author":"Nyquist","year":"2012","journal-title":"PloS One"},{"key":"10.1016\/j.ctrv.2026.103197_bb0315","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1007\/s00428-014-1627-1","article-title":"The combination of CD99 and NKX2.2, a transcriptional target of EWSR1-FLI1, is highly specific for the diagnosis of Ewing sarcoma","volume":"465","author":"Shibuya","year":"2014","journal-title":"Virchows Arch"},{"key":"10.1016\/j.ctrv.2026.103197_bb0320","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1007\/s11999-016-4779-2","article-title":"Survival in Mesenchymal chondrosarcoma varies based on age and tumor location: a survival analysis of the SEER database","volume":"475","author":"Schneiderman","year":"2017","journal-title":"Clin Orthop Relat Res"},{"key":"10.1016\/j.ctrv.2026.103197_bb0325","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.ejca.2014.11.007","article-title":"Mesenchymal chondrosarcoma: prognostic factors and outcome in 113 patients. A European musculoskeletal oncology society study","volume":"51","author":"Frezza","year":"2015","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ctrv.2026.103197_bb0330","article-title":"Mesenchymal chondrosarcoma of bone and soft tissue: a systematic review of 107 patients in the past 20 years","volume":"10","author":"Xu","year":"2015","journal-title":"PloS One"},{"key":"10.1016\/j.ctrv.2026.103197_bb0335","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1002\/jso.24567","article-title":"Mesenchymal chondrosarcoma: a Japanese musculoskeletal oncology group (JMOG) study on 57 patients","volume":"115","author":"Tsuda","year":"2017","journal-title":"J Surg Oncol"},{"key":"10.1016\/j.ctrv.2026.103197_bb0340","doi-asserted-by":"crossref","DOI":"10.1186\/1758-3284-4-13","article-title":"Clear cell chondrosarcoma of the head and neck","volume":"4","author":"Mokhtari","year":"2012","journal-title":"Head Neck Oncol"},{"key":"10.1016\/j.ctrv.2026.103197_bb0345","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1007\/s00256-003-0668-3","article-title":"Clear cell chondrosarcoma: radiographic, computed tomographic, and magnetic resonance findings in 34 patients with pathologic correlation","volume":"32","author":"Collins","year":"2003","journal-title":"Skeletal Radiol"},{"key":"10.1016\/j.ctrv.2026.103197_bb0350","doi-asserted-by":"crossref","first-page":"676","DOI":"10.2106\/00004623-197658050-00018","article-title":"Chondrosarcoma: clear-cell variant. A report of sixteen cases","volume":"58","author":"Unni","year":"1976","journal-title":"J Bone Joint Surg Am"},{"key":"10.1016\/j.ctrv.2026.103197_bb0355","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.5858\/2006-130-1673-ACCCDD","article-title":"Aggressive clear cell chondrosarcomas: do distinctive characteristics exist?: a report of 4 cases","volume":"130","author":"Corradi","year":"2006","journal-title":"Arch Pathol Lab Med"},{"key":"10.1016\/j.ctrv.2026.103197_bb0360","doi-asserted-by":"crossref","first-page":"2537","DOI":"10.1097\/CORR.0000000000001266","article-title":"What factors are associated with treatment outcomes of Japanese patients with clear cell chondrosarcoma?","volume":"478","author":"Nakayama","year":"2020","journal-title":"Clin Orthop Relat Res"},{"key":"10.1016\/j.ctrv.2026.103197_bb0365","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbo.2019.100267","article-title":"Clear cell chondrosarcoma is an underestimated tumor: report of 7 cases and meta-analysis of the literature","volume":"19","author":"Klein","year":"2019","journal-title":"J Bone Oncol"},{"key":"10.1016\/j.ctrv.2026.103197_bb0370","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1007\/s00402-007-0353-4","article-title":"Clear cell chondrosarcoma of bone: long time follow-up of 18 cases","volume":"128","author":"Donati","year":"2008","journal-title":"Arch Orthop Trauma Surg"},{"key":"10.1016\/j.ctrv.2026.103197_bb0375","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1158\/1078-0432.CCR-13-1333","article-title":"Molecular pathways: Isocitrate dehydrogenase mutations in Cancer","volume":"22","author":"Clark","year":"2016","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ctrv.2026.103197_bb0380","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1007\/s40259-017-0237-2","article-title":"Metabolic enzymes in Sarcomagenesis: Progress toward biology and therapy","volume":"31","author":"Li","year":"2017","journal-title":"BioDrugs"},{"key":"10.1016\/j.ctrv.2026.103197_bb0385","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1038\/nature08617","article-title":"Cancer-associated IDH1 mutations produce 2-hydroxyglutarate","volume":"462","author":"Dang","year":"2009","journal-title":"Nature"},{"key":"10.1016\/j.ctrv.2026.103197_bb0390","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2021.651317","article-title":"The roles of 2-Hydroxyglutarate","volume":"9","author":"Du","year":"2021","journal-title":"Front Cell Dev Biol"},{"key":"10.1016\/j.ctrv.2026.103197_bb0395","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1016\/j.ccr.2010.11.015","article-title":"Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation","volume":"18","author":"Figueroa","year":"2010","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ctrv.2026.103197_bb0400","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1038\/s41467-025-56781-2","article-title":"D-2-hydroxyglutarate impairs DNA repair through epigenetic reprogramming","volume":"16","author":"Lang","year":"2025","journal-title":"Nat Commun"},{"key":"10.1016\/j.ctrv.2026.103197_bb0405","doi-asserted-by":"crossref","DOI":"10.1155\/2022\/7729968","article-title":"IDH1 mutation induces HIF-1alpha and confers angiogenic properties in chondrosarcoma JJ012 cells","volume":"2022","author":"Hu","year":"2022","journal-title":"Dis Markers"},{"key":"10.1016\/j.ctrv.2026.103197_bb0410","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.molmed.2010.07.002","article-title":"IDH mutations in glioma and acute myeloid leukemia","volume":"16","author":"Dang","year":"2010","journal-title":"Trends Mol Med"},{"key":"10.1016\/j.ctrv.2026.103197_bb0415","doi-asserted-by":"crossref","first-page":"4415","DOI":"10.1002\/cam4.4019","article-title":"Prognostic importance of IDH mutations in chondrosarcoma: an individual patient data meta-analysis","volume":"10","author":"Vuong","year":"2021","journal-title":"Cancer Med"},{"key":"10.1016\/j.ctrv.2026.103197_bb0420","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1016\/j.jos.2021.07.024","article-title":"Prognostic impact of IDH mutations in chondrosarcoma","volume":"27","author":"Nakagawa","year":"2022","journal-title":"J Orthop Sci"},{"key":"10.1016\/j.ctrv.2026.103197_bb0425","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.humpath.2017.05.015","article-title":"Diagnostic utility of IDH1\/2 mutations to distinguish dedifferentiated chondrosarcoma from undifferentiated pleomorphic sarcoma of bone","volume":"65","author":"Chen","year":"2017","journal-title":"Hum Pathol"},{"key":"10.1016\/j.ctrv.2026.103197_bb0430","doi-asserted-by":"crossref","first-page":"11528","DOI":"10.1200\/JCO.2026.44.16_suppl.11528","article-title":"Genomic characterization of conventional, dedifferentiated, and mesenchymal chondrosarcoma: a 550-patient multicenter analysis","volume":"44","author":"Li","year":"2026","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2026.103197_bb0435","doi-asserted-by":"crossref","first-page":"998","DOI":"10.7150\/jca.22915","article-title":"IDH1\/2 mutations predict shorter survival in chondrosarcoma","volume":"9","author":"Lugowska","year":"2018","journal-title":"J Cancer"},{"key":"10.1016\/j.ctrv.2026.103197_bb0440","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.mrrev.2016.02.003","article-title":"Molecular genetics of the COL2A1-related disorders","volume":"768","author":"Deng","year":"2016","journal-title":"Mutat Res Rev Mutat Res"},{"key":"10.1016\/j.ctrv.2026.103197_bb0445","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1002\/humu.22915","article-title":"Mutation update for COL2A1 gene variants associated with type II Collagenopathies","volume":"37","author":"Barat-Houari","year":"2016","journal-title":"Hum Mutat"},{"key":"10.1016\/j.ctrv.2026.103197_bb0450","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1016\/S0046-8177(96)90341-X","article-title":"Chondrocytic cell differentiation in clear cell chondrosarcoma","volume":"27","author":"Aigner","year":"1996","journal-title":"Hum Pathol"},{"key":"10.1016\/j.ctrv.2026.103197_bb0455","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1038\/ng.2668","article-title":"Frequent mutation of the major cartilage collagen gene COL2A1 in chondrosarcoma","volume":"45","author":"Tarpey","year":"2013","journal-title":"Nat Genet"},{"key":"10.1016\/j.ctrv.2026.103197_bb0460","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a026070","article-title":"p53 in the DNA-damage-repair process","volume":"6","author":"Williams","year":"2016","journal-title":"Cold Spring Harb Perspect Med"},{"key":"10.1016\/j.ctrv.2026.103197_bb0465","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbcan.2021.188556","article-title":"Tumor suppressor p53: biology, signaling pathways, and therapeutic targeting","volume":"1876","author":"Hernandez Borrero","year":"2021","journal-title":"Biochim Biophys Acta Rev Cancer"},{"key":"10.1016\/j.ctrv.2026.103197_bb0470","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.critrevonc.2018.09.001","article-title":"Chondrosarcoma: an overview of clinical behavior, molecular mechanisms mediated drug resistance and potential therapeutic targets","volume":"131","author":"Nazeri","year":"2018","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.ctrv.2026.103197_bb0475","first-page":"284","article-title":"TP53 gene aberrations in chondromatous neoplasms: correlation with immunohistochemical p53 accumulation and MDM2 expression","volume":"82","author":"Blasenbreu","year":"1998","journal-title":"Verh Dtsch Ges Pathol"},{"key":"10.1016\/j.ctrv.2026.103197_bb0480","doi-asserted-by":"crossref","first-page":"2324","DOI":"10.1002\/(SICI)1097-0142(19981201)83:11<2324::AID-CNCR12>3.0.CO;2-U","article-title":"Altered p53 is associated with aggressive behavior of chondrosarcoma: a long term follow-up study","volume":"83","author":"Oshiro","year":"1998","journal-title":"Cancer"},{"key":"10.1016\/j.ctrv.2026.103197_bb0485","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1101\/gad.1941710","article-title":"The Mdm2-p53 relationship evolves: Mdm2 swings both ways as an oncogene and a tumor suppressor","volume":"24","author":"Manfredi","year":"2010","journal-title":"Genes Dev"},{"key":"10.1016\/j.ctrv.2026.103197_bb0490","doi-asserted-by":"crossref","first-page":"2843","DOI":"10.1111\/j.1582-4934.2008.00406.x","article-title":"Central chondrosarcoma progression is associated with pRb pathway alterations: CDK4 down-regulation and p16 overexpression inhibit cell growth in vitro","volume":"13","author":"Schrage","year":"2009","journal-title":"J Cell Mol Med"},{"key":"10.1016\/j.ctrv.2026.103197_bb0495","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1002\/gcc.21974","article-title":"Genetic characterization of mesenchymal, clear cell, and dedifferentiated chondrosarcoma","volume":"51","author":"Meijer","year":"2012","journal-title":"Genes Chromosomes Cancer"},{"key":"10.1016\/j.ctrv.2026.103197_bb0500","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1016\/S1470-2045(12)70474-6","article-title":"Effect of the MDM2 antagonist RG7112 on the P53 pathway in patients with MDM2-amplified, well-differentiated or dedifferentiated liposarcoma: an exploratory proof-of-mechanism study","volume":"13","author":"Ray-Coquard","year":"2012","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ctrv.2026.103197_bb0505","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/S1535-6108(02)00102-2","article-title":"The RB and p53 pathways in cancer","volume":"2","author":"Sherr","year":"2002","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ctrv.2026.103197_bb0510","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/S0736-0266(00)00022-X","article-title":"Alterations in the regulatory pathway involving p16, pRb and cdk4 in human chondrosarcoma","volume":"19","author":"Asp","year":"2001","journal-title":"J Orthop Res"},{"key":"10.1016\/j.ctrv.2026.103197_bb0515","doi-asserted-by":"crossref","DOI":"10.3389\/fgene.2021.759129","article-title":"Hereditary multiple exostoses-a review of the molecular background, diagnostics, and potential therapeutic strategies","volume":"12","author":"Bukowska-Olech","year":"2021","journal-title":"Front Genet"},{"key":"10.1016\/j.ctrv.2026.103197_bb0520","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1086\/301726","article-title":"Mutations in the EXT1 and EXT2 genes in hereditary multiple exostoses","volume":"62","author":"Wuyts","year":"1998","journal-title":"Am J Hum Genet"},{"key":"10.1016\/j.ctrv.2026.103197_bb0525","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1086\/302532","article-title":"EXT-mutation analysis and loss of heterozygosity in sporadic and hereditary osteochondromas and secondary chondrosarcomas","volume":"65","author":"Bovee","year":"1999","journal-title":"Am J Hum Genet"},{"key":"10.1016\/j.ctrv.2026.103197_bb0530","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1136\/jmg.38.7.430","article-title":"Genotype-phenotype correlation in hereditary multiple exostoses","volume":"38","author":"Francannet","year":"2001","journal-title":"J Med Genet"},{"key":"10.1016\/j.ctrv.2026.103197_bb0535","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1038\/onc.2011.311","article-title":"Secondary peripheral chondrosarcoma evolving from osteochondroma as a result of outgrowth of cells with functional EXT","volume":"31","author":"de Andrea","year":"2012","journal-title":"Oncogene"},{"key":"10.1016\/j.ctrv.2026.103197_bb0540","doi-asserted-by":"crossref","first-page":"24","DOI":"10.2106\/JBJS.N.00121","article-title":"Intraosseous atypical chondroid tumor or chondrosarcoma grade 1 in patients with multiple osteochondromas","volume":"97","author":"Goud","year":"2015","journal-title":"J Bone Joint Surg Am"},{"key":"10.1016\/j.ctrv.2026.103197_bb0545","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1302\/0301-620X.84B1.0840093","article-title":"Risk factors for survival and local control in chondrosarcoma of bone","volume":"84","author":"Fiorenza","year":"2002","journal-title":"J Bone Joint Surg Br"},{"key":"10.1016\/j.ctrv.2026.103197_bb0550","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1016\/j.ejso.2018.05.033","article-title":"The role of surgical margins in chondrosarcoma","volume":"44","author":"Stevenson","year":"2018","journal-title":"Eur J Surg Oncol"},{"key":"10.1016\/j.ctrv.2026.103197_bb0555","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1155\/2000\/635246","article-title":"Chondrosarcoma of the pelvis: oncologic and functional outcome","volume":"4","author":"Wirbel","year":"2000","journal-title":"Sarcoma"},{"key":"10.1016\/j.ctrv.2026.103197_bb0560","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1302\/0301-620X.101B3.BJJ-2018-0881.R1","article-title":"Locally recurrent chondrosarcoma of the pelvis and limbs can only be controlled by wide local excision","volume":"101-b","author":"Laitinen","year":"2019","journal-title":"Bone Joint J"},{"key":"10.1016\/j.ctrv.2026.103197_bb0565","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1097\/CORR.0000000000000632","article-title":"Does resection of the primary tumor improve survival in patients with metastatic chondrosarcoma?","volume":"477","author":"Song","year":"2019","journal-title":"Clin Orthop Relat Res"},{"key":"10.1016\/j.ctrv.2026.103197_bb0570","doi-asserted-by":"crossref","first-page":"316","DOI":"10.2106\/JBJS.17.00105","article-title":"Conventional primary central chondrosarcoma of the pelvis: prognostic factors and outcome of surgical treatment in 162 patients","volume":"100","author":"Bus","year":"2018","journal-title":"J Bone Joint Surg Am"},{"key":"10.1016\/j.ctrv.2026.103197_bb0575","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1097\/CORR.0000000000000766","article-title":"Can navigation improve the ability to achieve tumor-free margins in pelvic and sacral primary bone sarcoma resections? A historically controlled study","volume":"477","author":"Bosma","year":"2019","journal-title":"Clin Orthop Relat Res"},{"key":"10.1016\/j.ctrv.2026.103197_bb0580","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1016\/j.ejso.2020.05.025","article-title":"Navigation-assisted pelvic resections and reconstructions for periacetabular chondrosarcomas","volume":"47","author":"Fujiwara","year":"2021","journal-title":"Eur J Surg Oncol"},{"key":"10.1016\/j.ctrv.2026.103197_bb0585","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1097\/BLO.0b013e318146830f","article-title":"Surgical management of conventional grade I chondrosarcoma of long bones","volume":"463","author":"Leerapun","year":"2007","journal-title":"Clin Orthop Relat Res"},{"key":"10.1016\/j.ctrv.2026.103197_bb0590","doi-asserted-by":"crossref","first-page":"149","DOI":"10.2106\/00004623-197355010-00015","article-title":"On the setting properties of acrylic bone cement","volume":"55","author":"Meyer","year":"1973","journal-title":"J Bone Joint Surg Am"},{"key":"10.1016\/j.ctrv.2026.103197_bb0595","doi-asserted-by":"crossref","first-page":"e249","DOI":"10.5435\/JAAOS-D-16-00218","article-title":"Lower extremity megaprostheses in orthopaedic oncology","volume":"26","author":"Lozano Calder\u00f3n","year":"2018","journal-title":"J Am Acad Orthop Surg"},{"key":"10.1016\/j.ctrv.2026.103197_bb0600","doi-asserted-by":"crossref","first-page":"e319","DOI":"10.5435\/JAAOS-D-19-00219","article-title":"Endoprosthetic reconstruction of the upper extremity in oncologic surgery","volume":"28","author":"Hennessy","year":"2020","journal-title":"J Am Acad Orthop Surg"},{"key":"10.1016\/j.ctrv.2026.103197_bb0605","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1007\/s10434-004-1171-3","article-title":"The indications for and the prognostic significance of amputation as the primary surgical procedure for localized soft tissue sarcoma of the extremity","volume":"12","author":"Ghert","year":"2005","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.ctrv.2026.103197_bb0610","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1245\/s10434-017-6240-5","article-title":"Amputation for extremity sarcoma: contemporary indications and outcomes","volume":"25","author":"Erstad","year":"2018","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.ctrv.2026.103197_bb0615","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1302\/0301-620X.87B11.16621","article-title":"Surgical treatment and outcome of conventional pelvic chondrosarcoma","volume":"87","author":"Donati","year":"2005","journal-title":"J Bone Joint Surg Br"},{"key":"10.1016\/j.ctrv.2026.103197_bb0620","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1302\/0301-620X.95B1.29131","article-title":"Hindquarter amputation: is it still needed and what are the outcomes?","volume":"95-b","author":"Grimer","year":"2013","journal-title":"Bone Joint J"},{"key":"10.1016\/j.ctrv.2026.103197_bb0625","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1245\/s10434-017-5806-6","article-title":"Oncologic outcome and quality of life after hindquarter amputation for sarcoma: is it worth it?","volume":"25","author":"van Houdt","year":"2018","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.ctrv.2026.103197_bb0630","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1186\/s12885-020-07502-z","article-title":"Limb salvage versus amputation in patients with osteosarcoma of the extremities: an update in the modern era using the National Cancer Database","volume":"20","author":"Evans","year":"2020","journal-title":"BMC Cancer"},{"key":"10.1016\/j.ctrv.2026.103197_bb0635","doi-asserted-by":"crossref","first-page":"731","DOI":"10.2106\/00004623-197860060-00002","article-title":"Resection and reconstruction for primary neoplasms involving the innominate bone","volume":"60","author":"Enneking","year":"1978","journal-title":"J Bone Joint Surg Am"},{"key":"10.1016\/j.ctrv.2026.103197_bb0640","doi-asserted-by":"crossref","first-page":"2000","DOI":"10.1007\/s11999-012-2271-1","article-title":"Does limb-salvage surgery offer patients better quality of life and functional capacity than amputation?","volume":"470","author":"Malek","year":"2012","journal-title":"Clin Orthop Relat Res"},{"key":"10.1016\/j.ctrv.2026.103197_bb0645","doi-asserted-by":"crossref","DOI":"10.1177\/15330338261425345","article-title":"Advances in radiation therapy for primary bone malignancies","volume":"25","author":"Li","year":"2026","journal-title":"Technol Cancer Res Treat"},{"key":"10.1016\/j.ctrv.2026.103197_bb0650","doi-asserted-by":"crossref","first-page":"373","DOI":"10.14338\/IJPT-16-00018.1","article-title":"High-dose proton beam-based radiation therapy in the Management of Extracranial Chondrosarcomas","volume":"3","author":"Bhatt","year":"2017","journal-title":"Int J Part Ther"},{"key":"10.1016\/j.ctrv.2026.103197_bb0655","doi-asserted-by":"crossref","DOI":"10.1155\/2019\/4878512","article-title":"Revisiting the role of radiation therapy in chondrosarcoma: a National Cancer Database Study","volume":"2019","author":"Catanzano","year":"2019","journal-title":"Sarcoma"},{"key":"10.1016\/j.ctrv.2026.103197_bb0660","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1159\/000469680","article-title":"Proton and carbon ion therapy of intracranial gliomas","volume":"32","author":"Combs","year":"2018","journal-title":"Prog Neurol Surg"},{"key":"10.1016\/j.ctrv.2026.103197_bb0665","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1002\/hed.25479","article-title":"Proton therapy for skull base tumors: a review of clinical outcomes for chordomas and chondrosarcomas","volume":"41","author":"Mercado","year":"2019","journal-title":"Head Neck"},{"key":"10.1016\/j.ctrv.2026.103197_bb0670","doi-asserted-by":"crossref","first-page":"432","DOI":"10.3171\/jns.1999.91.3.0432","article-title":"Proton radiation therapy for chordomas and chondrosarcomas of the skull base","volume":"91","author":"Hug","year":"1999","journal-title":"J Neurosurg"},{"key":"10.1016\/j.ctrv.2026.103197_bb0675","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1097\/00000478-199911000-00007","article-title":"Chondrosarcoma of the base of the skull: a clinicopathologic study of 200 cases with emphasis on its distinction from chordoma","volume":"23","author":"Rosenberg","year":"1999","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.ctrv.2026.103197_bb0680","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1007\/s00066-003-1065-5","article-title":"Radiation therapy for chordoma and chondrosarcoma of the skull base and the cervical spine. Prognostic factors and patterns of failure","volume":"179","author":"No\u00ebl","year":"2003","journal-title":"Strahlenther Onkol"},{"key":"10.1016\/j.ctrv.2026.103197_bb0685","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.ijrobp.2005.02.023","article-title":"Results of spot-scanning proton radiation therapy for chordoma and chondrosarcoma of the skull base: the Paul Scherrer Institut experience","volume":"63","author":"Weber","year":"2005","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ctrv.2026.103197_bb0690","doi-asserted-by":"crossref","first-page":"e379","DOI":"10.3928\/01477447-20120222-30","article-title":"Chondrosarcomas revisited","volume":"35","author":"Mavrogenis","year":"2012","journal-title":"Orthopedics"},{"key":"10.1016\/j.ctrv.2026.103197_bb0695","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.ijrobp.2024.09.030","article-title":"Proton-based radiation therapy for skull base chondrosarcomas in children and adolescents: 40-year experience from the Massachusetts General Hospital","volume":"121","author":"Ioakeim-Ioannidou","year":"2024","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ctrv.2026.103197_bb0700","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1007\/s00066-003-1120-2","article-title":"Carbon ion radiotherapy for chordomas and low-grade chondrosarcomas of the skull base. Results in 67 patients","volume":"179","author":"Schulz-Ertner","year":"2003","journal-title":"Strahlenther Onkol"},{"key":"10.1016\/j.ctrv.2026.103197_bb0705","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.ijrobp.2006.08.027","article-title":"Carbon ion radiotherapy of skull base chondrosarcomas","volume":"67","author":"Schulz-Ertner","year":"2007","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ctrv.2026.103197_bb0710","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1002\/cncr.28606","article-title":"High control rate in patients with chondrosarcoma of the skull base after carbon ion therapy: first report of long-term results","volume":"120","author":"Uhl","year":"2014","journal-title":"Cancer"},{"key":"10.1016\/j.ctrv.2026.103197_bb0715","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1093\/neuonc\/nov154","article-title":"Long-term outcomes and prognostic factors of skull-base chondrosarcoma patients treated with pencil-beam scanning proton therapy at the Paul Scherrer Institute","volume":"18","author":"Weber","year":"2016","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.ctrv.2026.103197_bb0720","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13174423","article-title":"Particle radiotherapy for skull base chondrosarcoma: a clinical series from Italian National Center for oncological Hadrontherapy","volume":"13","author":"Riva","year":"2021","journal-title":"Cancers (Basel)."},{"key":"10.1016\/j.ctrv.2026.103197_bb0725","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1093\/neuonc\/noaf289","article-title":"Prospective, randomized dose-escalation trial with proton-based radiation for skull base and cervical spine chondrosarcomas: 30-year outcomes from PROG 85-26","volume":"28","author":"Ioakeim-Ioannidou","year":"2026","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.ctrv.2026.103197_bb0730","article-title":"Randomised trial of proton vs. carbon ion radiation therapy in patients with low and intermediate grade chondrosarcoma of the skull base, clinical phase III study","volume":"10","author":"Nikoghosyan","year":"2010","journal-title":"BMC Cancer"},{"key":"10.1016\/j.ctrv.2026.103197_bb0735","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15235579","article-title":"Five-fraction proton therapy for the treatment of skull base chordomas and chondrosarcomas: early results of a prospective series and description of a clinical trial","volume":"15","author":"Sallabanda","year":"2023","journal-title":"Cancers (Basel)."},{"key":"10.1016\/j.ctrv.2026.103197_bb0740","first-page":"2407","article-title":"Combined radiotherapy and razoxane in the treatment of chondrosarcomas and chordomas","volume":"26","author":"Rhomberg","year":"2006","journal-title":"Anticancer Res"},{"key":"10.1016\/j.ctrv.2026.103197_bb0745","doi-asserted-by":"crossref","DOI":"10.3390\/cancers11121918","article-title":"Inhibition of PARP sensitizes chondrosarcoma cell lines to chemo- and radiotherapy irrespective of the IDH1 or IDH2 mutation status","volume":"11","author":"Venneker","year":"2019","journal-title":"Cancers (Basel)."},{"key":"10.1016\/j.ctrv.2026.103197_bb0750","doi-asserted-by":"crossref","DOI":"10.3390\/biom14091071","article-title":"Radiosensitizing effect of PARP inhibition on chondrosarcoma and chondrocyte cells is dependent on radiation LET","volume":"14","author":"Gilbert","year":"2024","journal-title":"Biomolecules"},{"key":"10.1016\/j.ctrv.2026.103197_bb0755","doi-asserted-by":"crossref","first-page":"6655","DOI":"10.2147\/IJN.S390056","article-title":"Proof of concept of the radiosensitizing effect of gadolinium oxide nanoparticles in cell spheroids and a tumor-implanted murine model of chondrosarcoma","volume":"17","author":"Aloy","year":"2022","journal-title":"Int J Nanomedicine"},{"key":"10.1016\/j.ctrv.2026.103197_bb0760","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.canlet.2021.02.002","article-title":"Targeting cancer stem cells by disulfiram and copper sensitizes radioresistant chondrosarcoma to radiation","volume":"505","author":"Wang","year":"2021","journal-title":"Cancer Lett"},{"key":"10.1016\/j.ctrv.2026.103197_bb0765","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1002\/jso.25502","article-title":"A prospective clinical trial of proton therapy for chordoma and chondrosarcoma: feasibility assessment","volume":"120","author":"Baumann","year":"2019","journal-title":"J Surg Oncol"},{"key":"10.1016\/j.ctrv.2026.103197_bb0770","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1007\/s11864-022-00951-7","article-title":"Systemic therapy for chondrosarcoma","volume":"23","author":"Rock","year":"2022","journal-title":"Curr Treat Options Oncol"},{"key":"10.1016\/j.ctrv.2026.103197_bb0775","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/S1470-2045(05)70282-5","article-title":"Emerging pathways in the development of chondrosarcoma of bone and implications for targeted treatment","volume":"6","author":"Bov\u00e9e","year":"2005","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ctrv.2026.103197_bb0780","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1093\/annonc\/mdr512","article-title":"Restoration of chemosensitivity for doxorubicin and cisplatin in chondrosarcoma in vitro: BCL-2 family members cause chemoresistance","volume":"23","author":"van Oosterwijk","year":"2012","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2026.103197_bb0785","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1002\/jor.1100170619","article-title":"Multidrug resistance-1 and p-glycoprotein in human chondrosarcoma cell lines: expression correlates with decreased intracellular doxorubicin and in vitro chemoresistance","volume":"17","author":"Wyman","year":"1999","journal-title":"J Orthop Res"},{"key":"10.1016\/j.ctrv.2026.103197_bb0790","doi-asserted-by":"crossref","first-page":"566","DOI":"10.3390\/curroncol31010040","article-title":"A systematic review of adjuvant chemotherapy in localized dedifferentiated chondrosarcoma","volume":"31","author":"Tsukamoto","year":"2024","journal-title":"Curr Oncol"},{"key":"10.1016\/j.ctrv.2026.103197_bb0795","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1177\/030089160709300503","article-title":"Mesenchymal chondrosarcoma. An analysis of patients treated at a single institution","volume":"93","author":"Cesari","year":"2007","journal-title":"Tumori"},{"key":"10.1016\/j.ctrv.2026.103197_bb0800","doi-asserted-by":"crossref","first-page":"3159","DOI":"10.1002\/cncr.28845","article-title":"Outcome of advanced, unresectable conventional central chondrosarcoma","volume":"120","author":"van Maldegem","year":"2014","journal-title":"Cancer"},{"key":"10.1016\/j.ctrv.2026.103197_bb0805","doi-asserted-by":"crossref","DOI":"10.3390\/ijms252313003","article-title":"High-throughput drug screening in chondrosarcoma cells identifies effective antineoplastic agents independent of IDH mutation","volume":"25","author":"Li","year":"2024","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.ctrv.2026.103197_bb0810","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1038\/nature14011","article-title":"Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients","volume":"515","author":"Herbst","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.ctrv.2026.103197_bb0815","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1038\/nature13954","article-title":"PD-1 blockade induces responses by inhibiting adaptive immune resistance","volume":"515","author":"Tumeh","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.ctrv.2026.103197_bb0820","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1038\/s41588-018-0312-8","article-title":"Tumor mutational load predicts survival after immunotherapy across multiple cancer types","volume":"51","author":"Samstein","year":"2019","journal-title":"Nat Genet"},{"key":"10.1016\/j.ctrv.2026.103197_bb0825","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/s13073-017-0424-2","article-title":"Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden","volume":"9","author":"Chalmers","year":"2017","journal-title":"Genome Med"},{"key":"10.1016\/j.ctrv.2026.103197_bb0830","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1186\/s13045-020-00891-5","article-title":"PD1\/PD-L1 targeting in advanced soft-tissue sarcomas: a pooled analysis of phase II trials","volume":"13","author":"Italiano","year":"2020","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.ctrv.2026.103197_bb0835","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1001\/jamaoncol.2017.1617","article-title":"Use of PD-1 targeting, macrophage infiltration, and IDO pathway activation in sarcomas: a phase 2 clinical trial","volume":"4","author":"Toulmonde","year":"2018","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.ctrv.2026.103197_bb0840","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1016\/S1470-2045(17)30624-1","article-title":"Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial","volume":"18","author":"Tawbi","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ctrv.2026.103197_bb0845","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1016\/S1470-2045(18)30006-8","article-title":"Nivolumab with or without ipilimumab treatment for metastatic sarcoma (Alliance A091401): two open-label, non-comparative, randomised, phase 2 trials","volume":"19","author":"D\u2019Angelo","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ctrv.2026.103197_bb0850","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1177\/1724600818774464","article-title":"Expression of PD-L1\/PD-L2 is associated with high proliferation index of Ki-67 but not with TP53 overexpression in chondrosarcoma","volume":"33","author":"Yang","year":"2018","journal-title":"Int J Biol Markers"},{"key":"10.1016\/j.ctrv.2026.103197_bb0855","doi-asserted-by":"crossref","DOI":"10.1002\/cncr.35628","article-title":"Nivolumab and sunitinib in patients with advanced bone sarcomas: a multicenter, single-arm, phase 2 trial","volume":"131","author":"Palmerini","year":"2025","journal-title":"Cancer"},{"key":"10.1016\/j.ctrv.2026.103197_bb0860","doi-asserted-by":"crossref","first-page":"11510","DOI":"10.1200\/JCO.2026.44.16_suppl.11510","article-title":"Phase 1\/2 study of YL201, an anti-B7H3 antibody\u2013drug conjugate (ADC), in patients with relapsed or refractory (R\/R) Ewing sarcoma and chondrosarcoma","volume":"44","author":"Xie","year":"2026","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2026.103197_bb0865","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/S0046-8177(00)80248-8","article-title":"Microvasculature and VEGF expression in cartilaginous tumors","volume":"31","author":"Ayala","year":"2000","journal-title":"Hum Pathol"},{"key":"10.1016\/j.ctrv.2026.103197_bb0870","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1590\/S1807-59322011000900015","article-title":"Analysis of angiogenic factors and cyclooxygenase-2 expression in cartilaginous tumors- clinical and histological correlation","volume":"66","author":"Cintra","year":"2011","journal-title":"Clinics (Sao Paulo)"},{"key":"10.1016\/j.ctrv.2026.103197_bb0875","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/s13045-019-0718-5","article-title":"Recent advances on anti-angiogenesis receptor tyrosine kinase inhibitors in cancer therapy","volume":"12","author":"Qin","year":"2019","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.ctrv.2026.103197_bb0880","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1016\/S0140-6736(12)60651-5","article-title":"Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial","volume":"379","author":"van der Graaf","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.ctrv.2026.103197_bb0885","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1002\/cncr.32515","article-title":"Results of a prospective phase 2 study of pazopanib in patients with surgically unresectable or metastatic chondrosarcoma","volume":"126","author":"Chow","year":"2020","journal-title":"Cancer"},{"key":"10.1016\/j.ctrv.2026.103197_bb0890","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2018.00045","article-title":"Clinical benefit of Pazopanib in a patient with metastatic chondrosarcoma: a case report and review of the literature","volume":"8","author":"Tsavaris","year":"2018","journal-title":"Front Oncol"},{"key":"10.1016\/j.ctrv.2026.103197_bb0895","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1007\/s12032-017-1030-2","article-title":"Clinical benefit of antiangiogenic therapy in advanced and metastatic chondrosarcoma","volume":"34","author":"Jones","year":"2017","journal-title":"Med Oncol"},{"key":"10.1016\/j.ctrv.2026.103197_bb0900","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15092617","article-title":"A retrospective multi-institutional cohort analysis of clinical characteristics and outcomes in dedifferentiated chondrosarcoma","volume":"15","author":"Bui","year":"2023","journal-title":"Cancers (Basel)."},{"key":"10.1016\/j.ctrv.2026.103197_bb0905","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1200\/JCO.19.02492","article-title":"Phase I study of the mutant IDH1 inhibitor Ivosidenib: safety and clinical activity in patients with advanced chondrosarcoma","volume":"38","author":"Tap","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2026.103197_bb0910","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.1158\/1078-0432.CCR-24-4128","article-title":"Phase I study of the mutant IDH1 inhibitor ivosidenib: long-term safety and clinical activity in patients with conventional chondrosarcoma","volume":"31","author":"Tap","year":"2025","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ctrv.2026.103197_bb0915","doi-asserted-by":"crossref","first-page":"2988","DOI":"10.1158\/1078-0432.CCR-23-0974","article-title":"Preclinical characterization and phase I trial results of INBRX-109, a third-generation, recombinant, humanized, death receptor 5 agonist antibody, in chondrosarcoma","volume":"29","author":"Subbiah","year":"2023","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ctrv.2026.103197_bb0920","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1186\/s12885-018-4303-z","article-title":"Apatinib for advanced sarcoma: results from multiple institutions\u2019 off-label use in China","volume":"18","author":"Xie","year":"2018","journal-title":"BMC Cancer"},{"key":"10.1016\/j.ctrv.2026.103197_bb0925","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.ejca.2021.03.039","article-title":"Efficacy and safety of regorafenib in patients with metastatic or locally advanced chondrosarcoma: results of a non-comparative, randomised, double-blind, placebo controlled, multicentre phase II study","volume":"150","author":"Duffaud","year":"2021","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ctrv.2026.103197_bb0930","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/s13569-018-0107-9","article-title":"A phase II study of temsirolimus and liposomal doxorubicin for patients with recurrent and refractory bone and soft tissue sarcomas","volume":"8","author":"Trucco","year":"2018","journal-title":"Clin Sarcoma Res"},{"key":"10.1016\/j.ctrv.2026.103197_bb0935","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13102474","article-title":"A phase Ib clinical trial of metformin and chloroquine in patients with IDH1-mutated solid tumors","volume":"13","author":"Khurshed","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.ctrv.2026.103197_bb0940","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1634\/theoncologist.2010-0265","article-title":"Phase II study of sequential gemcitabine followed by docetaxel for recurrent Ewing sarcoma, osteosarcoma, or unresectable or locally recurrent chondrosarcoma: results of sarcoma Alliance for research through collaboration study 003","volume":"17","author":"Fox","year":"2012","journal-title":"Oncologist"},{"key":"10.1016\/j.ctrv.2026.103197_bb0945","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1007\/s40265-017-0813-2","article-title":"Enasidenib: first global approval","volume":"77","author":"Kim","year":"2017","journal-title":"Drugs"},{"key":"10.1016\/j.ctrv.2026.103197_bb0950","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1080\/17512433.2018.1477585","article-title":"Enasidenib for the treatment of acute myeloid leukemia","volume":"11","author":"Dugan","year":"2018","journal-title":"Expert Rev Clin Pharmacol"},{"key":"10.1016\/j.ctrv.2026.103197_bb0955","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1007\/s40265-018-0978-3","article-title":"Ivosidenib: first global approval","volume":"78","author":"Dhillon","year":"2018","journal-title":"Drugs"},{"key":"10.1016\/j.ctrv.2026.103197_bb0960","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1007\/s40265-023-01844-1","article-title":"Olutasidenib: first approval","volume":"83","author":"Kang","year":"2023","journal-title":"Drugs"},{"key":"10.1016\/j.ctrv.2026.103197_bb0965","doi-asserted-by":"crossref","first-page":"4358","DOI":"10.1182\/bloodadvances.2023009854","article-title":"Olutasidenib: from bench to bedside","volume":"7","author":"Venugopal","year":"2023","journal-title":"Blood Adv"},{"key":"10.1016\/j.ctrv.2026.103197_bb0970","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1007\/s40265-024-02097-2","article-title":"Vorasidenib: first approval","volume":"84","author":"Lamb","year":"2024","journal-title":"Drugs"},{"key":"10.1016\/j.ctrv.2026.103197_bb0975","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1016\/j.apsb.2021.03.005","article-title":"Preclinical efficacy against acute myeloid leukaemia of SH1573, a novel mutant IDH2 inhibitor approved for clinical trials in China","volume":"11","author":"Wang","year":"2021","journal-title":"Acta Pharm Sin B"},{"key":"10.1016\/j.ctrv.2026.103197_bb0980","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1126\/science.1236062","article-title":"An inhibitor of mutant IDH1 delays growth and promotes differentiation of glioma cells","volume":"340","author":"Rohle","year":"2013","journal-title":"Science"},{"key":"10.1016\/j.ctrv.2026.103197_bb0985","article-title":"Treatment with a small molecule mutant IDH1 inhibitor suppresses tumorigenic activity and decreases production of the Oncometabolite 2-Hydroxyglutarate in human chondrosarcoma cells","volume":"10","author":"Li","year":"2015","journal-title":"PloS One"},{"key":"10.1016\/j.ctrv.2026.103197_bb0990","article-title":"Mutant IDH1 depletion downregulates integrins and impairs chondrosarcoma growth","volume":"12","author":"Li","year":"2020","journal-title":"Cancers (Basel)."},{"key":"10.1016\/j.ctrv.2026.103197_bb0995","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2024.105090","article-title":"A personalized medicine approach identifies enasidenib as an efficient treatment for IDH2 mutant chondrosarcoma","volume":"102","author":"Rey","year":"2024","journal-title":"EBioMedicine"},{"key":"10.1016\/j.ctrv.2026.103197_bb1000","doi-asserted-by":"crossref","first-page":"12505","DOI":"10.18632\/oncotarget.3723","article-title":"Inhibition of mutant IDH1 decreases D-2-HG levels without affecting tumorigenic properties of chondrosarcoma cell lines","volume":"6","author":"Suijker","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.ctrv.2026.103197_bb1005","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1016\/j.ccell.2015.11.006","article-title":"Extreme vulnerability of IDH1 mutant cancers to NAD+ depletion","volume":"28","author":"Tateishi","year":"2015","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ctrv.2026.103197_bb1010","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15143603","article-title":"IDH mutations in chondrosarcoma: case closed or not?","volume":"15","author":"Venneker","year":"2023","journal-title":"Cancers (Basel)."},{"key":"10.1016\/j.ctrv.2026.103197_bb1015","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.1016\/j.biocel.2007.02.007","article-title":"TRAIL signalling: decisions between life and death","volume":"39","author":"Falschlehner","year":"2007","journal-title":"Int J Biochem Cell Biol"},{"key":"10.1016\/j.ctrv.2026.103197_bb1020","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1038\/nrc.2017.28","article-title":"Exploring the TRAILs less travelled: TRAIL in cancer biology and therapy","volume":"17","author":"von Karstedt","year":"2017","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.ctrv.2026.103197_bb1025","doi-asserted-by":"crossref","first-page":"1384795","DOI":"10.3389\/fmolb.2024.1384795","article-title":"Targeting death receptor 5 (DR5) for the imaging and treatment of primary bone and soft tissue tumors: an update of the literature","volume":"11","author":"Gamie","year":"2024","journal-title":"Front Mol Biosci"},{"key":"10.1016\/j.ctrv.2026.103197_bb1030","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2025.1549808","article-title":"Advances in the study of death receptor 5","volume":"16","author":"Qiao","year":"2025","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.ctrv.2026.103197_bb1035","article-title":"Turn TRAIL into better anticancer therapeutic through TRAIL fusion proteins","volume":"14","author":"Wang","year":"2025","journal-title":"Cancer Med"},{"key":"10.1016\/j.ctrv.2026.103197_bb1040","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s40487-024-00317-z","article-title":"Advancing systemic therapy in chondrosarcoma: new horizons","volume":"13","author":"Li","year":"2025","journal-title":"Oncol Ther"},{"key":"10.1016\/j.ctrv.2026.103197_bb1045","doi-asserted-by":"crossref","first-page":"11504","DOI":"10.1200\/JCO.2026.44.16_suppl.11504","article-title":"The tetravalent death receptor 5 (DR5) agonist ozekibart (INBRX-109) in conventional chondrosarcoma (CS): secondary efficacy endpoints from the randomized, registrational, phase 2 ChonDRAgon study","volume":"44","author":"Gelderblom","year":"2026","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2026.103197_bb1050","doi-asserted-by":"crossref","first-page":"2072","DOI":"10.1101\/gad.13.16.2072","article-title":"Indian hedgehog signaling regulates proliferation and differentiation of chondrocytes and is essential for bone formation","volume":"13","author":"St-Jacques","year":"1999","journal-title":"Genes Dev"},{"key":"10.1016\/j.ctrv.2026.103197_bb1055","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.chembiol.2017.02.010","article-title":"Hedgehog signaling: from basic biology to Cancer therapy","volume":"24","author":"Wu","year":"2017","journal-title":"Cell Chem Biol"},{"key":"10.1016\/j.ctrv.2026.103197_bb1060","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.3892\/or.2014.3372","article-title":"Hedgehog pathway inhibitor-4 suppresses malignant properties of chondrosarcoma cells by disturbing tumor ciliogenesis","volume":"32","author":"Xiang","year":"2014","journal-title":"Oncol Rep"},{"key":"10.1016\/j.ctrv.2026.103197_bb1065","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1158\/1535-7163.MCT-13-0731","article-title":"Hedgehog pathway inhibition in chondrosarcoma using the smoothened inhibitor IPI-926 directly inhibits sarcoma cell growth","volume":"13","author":"Campbell","year":"2014","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.ctrv.2026.103197_bb1070","series-title":"Results from a phase 2 randomized, placebo-controlled, double blind study of the hedgehog pathway antagonist IPI-926 in patients with advanced chondrosarcoma. Connective Tissue Oncology Society Annual Meeting","author":"Wagner","year":"2013"},{"key":"10.1016\/j.ctrv.2026.103197_bb1075","doi-asserted-by":"crossref","first-page":"2922","DOI":"10.1093\/annonc\/mdt391","article-title":"GDC-0449 in patients with advanced chondrosarcomas: a French sarcoma group\/US and French National Cancer Institute single-arm phase II collaborative study","volume":"24","author":"Italiano","year":"2013","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2026.103197_bb1080","doi-asserted-by":"crossref","first-page":"7906","DOI":"10.1038\/sj.onc.1208160","article-title":"Src family kinases, key regulators of signal transduction","volume":"23","author":"Parsons","year":"2004","journal-title":"Oncogene"},{"key":"10.1016\/j.ctrv.2026.103197_bb1085","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1634\/theoncologist.2009-0009","article-title":"The role of Src in solid tumors","volume":"14","author":"Wheeler","year":"2009","journal-title":"Oncologist"},{"key":"10.1016\/j.ctrv.2026.103197_bb1090","doi-asserted-by":"crossref","first-page":"2800","DOI":"10.1158\/0008-5472.CAN-06-3469","article-title":"Dasatinib inhibits migration and invasion in diverse human sarcoma cell lines and induces apoptosis in bone sarcoma cells dependent on SRC kinase for survival","volume":"67","author":"Shor","year":"2007","journal-title":"Cancer Res"},{"key":"10.1016\/j.ctrv.2026.103197_bb1095","doi-asserted-by":"crossref","first-page":"2501","DOI":"10.1158\/0008-5472.CAN-11-3015","article-title":"Phosphoproteomics identifies driver tyrosine kinases in sarcoma cell lines and tumors","volume":"72","author":"Bai","year":"2012","journal-title":"Cancer Res"},{"key":"10.1016\/j.ctrv.2026.103197_bb1100","doi-asserted-by":"crossref","first-page":"2518","DOI":"10.1158\/0008-5472.CAN-12-3023","article-title":"SRC signaling is crucial in the growth of synovial sarcoma cells","volume":"73","author":"Michels","year":"2013","journal-title":"Cancer Res"},{"key":"10.1016\/j.ctrv.2026.103197_bb1105","doi-asserted-by":"crossref","first-page":"6216","DOI":"10.1158\/0008-5472.CAN-08-4801","article-title":"Kinome profiling of chondrosarcoma reveals SRC-pathway activity and dasatinib as option for treatment","volume":"69","author":"Schrage","year":"2009","journal-title":"Cancer Res"},{"key":"10.1016\/j.ctrv.2026.103197_bb1110","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1038\/nrc2869","article-title":"Cartilage tumours and bone development: molecular pathology and possible therapeutic targets","volume":"10","author":"Bov\u00e9e","year":"2010","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.ctrv.2026.103197_bb1115","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1038\/bjc.2013.451","article-title":"Src kinases in chondrosarcoma chemoresistance and migration: dasatinib sensitises to doxorubicin in TP53 mutant cells","volume":"109","author":"van Oosterwijk","year":"2013","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ctrv.2026.103197_bb1120","article-title":"BMP-7 enhances cell migration and \u03b1v\u03b23 integrin expression via a c-Src-dependent pathway in human chondrosarcoma cells","volume":"9","author":"Chen","year":"2014","journal-title":"PloS One"},{"key":"10.1016\/j.ctrv.2026.103197_bb1125","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1002\/cncr.29858","article-title":"SARC009: phase 2 study of dasatinib in patients with previously treated, high-grade, advanced sarcoma","volume":"122","author":"Schuetze","year":"2016","journal-title":"Cancer"},{"key":"10.1016\/j.ctrv.2026.103197_bb1130","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1093\/jnci\/djq315","article-title":"Effect of multikinase inhibitors on caspase-independent cell death and DNA damage in HER2-overexpressing breast cancer cells","volume":"102","author":"Seoane","year":"2010","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.ctrv.2026.103197_bb1135","doi-asserted-by":"crossref","first-page":"4284","DOI":"10.1158\/1078-0432.CCR-07-5226","article-title":"Combined inhibition of c-Src and epidermal growth factor receptor abrogates growth and invasion of head and neck squamous cell carcinoma","volume":"14","author":"Koppikar","year":"2008","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ctrv.2026.103197_bb1140","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1038\/onc.2010.430","article-title":"Dasatinib sensitizes KRAS mutant colorectal tumors to cetuximab","volume":"30","author":"Dunn","year":"2011","journal-title":"Oncogene"},{"key":"10.1016\/j.ctrv.2026.103197_bb1145","first-page":"633","article-title":"Co-administration of NVP-AEW541 and dasatinib induces mitochondrial-mediated apoptosis through Bax activation in malignant human glioma cell lines","volume":"37","author":"Premkumar","year":"2010","journal-title":"Int J Oncol"},{"key":"10.1016\/j.ctrv.2026.103197_bb1150","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1016\/j.cell.2017.02.004","article-title":"mTOR signaling in growth, metabolism, and disease","volume":"168","author":"Saxton","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.ctrv.2026.103197_bb1155","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1038\/s41568-018-0074-8","article-title":"mTOR signalling and cellular metabolism are mutual determinants in cancer","volume":"18","author":"Mossmann","year":"2018","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.ctrv.2026.103197_bb1160","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbo.2019.100222","article-title":"Exploration of the chondrosarcoma metabolome; the mTOR pathway as an important pro-survival pathway","volume":"15","author":"Addie","year":"2019","journal-title":"J Bone Oncol."},{"key":"10.1016\/j.ctrv.2026.103197_bb1165","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0032458","article-title":"Inhibition of chondrosarcoma growth by mTOR inhibitor in an in vivo syngeneic rat model","volume":"7","author":"Perez","year":"2012","journal-title":"PloS One"},{"key":"10.1016\/j.ctrv.2026.103197_bb1170","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1007\/s00280-012-1968-x","article-title":"Clinical activity of mTOR inhibition in combination with cyclophosphamide in the treatment of recurrent unresectable chondrosarcomas","volume":"70","author":"Bernstein-Molho","year":"2012","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.ctrv.2026.103197_bb1175","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1038\/ng1531","article-title":"Loss of acetylation at Lys16 and trimethylation at Lys20 of histone H4 is a common hallmark of human cancer","volume":"37","author":"Fraga","year":"2005","journal-title":"Nat Genet"},{"key":"10.1016\/j.ctrv.2026.103197_bb1180","first-page":"47","article-title":"Histone deacetylase inhibitors (HDACIs): multitargeted anticancer agents","volume":"7","author":"Ververis","year":"2013","journal-title":"Biologics"},{"key":"10.1016\/j.ctrv.2026.103197_bb1185","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1002\/ijc.20372","article-title":"Histone deacetylase inhibitors: understanding a new wave of anticancer agents","volume":"112","author":"Villar-Garea","year":"2004","journal-title":"Int J Cancer"},{"key":"10.1016\/j.ctrv.2026.103197_bb1190","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1002\/ijc.21069","article-title":"Antitumor effects of histone deacetylase inhibitor on Ewing\u2019s family tumors","volume":"116","author":"Sakimura","year":"2005","journal-title":"Int J Cancer"},{"key":"10.1016\/j.ctrv.2026.103197_bb1195","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1158\/1078-0432.CCR-06-1696","article-title":"The effects of histone deacetylase inhibitors on the induction of differentiation in chondrosarcoma cells","volume":"13","author":"Sakimura","year":"2007","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ctrv.2026.103197_bb1200","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12123589","article-title":"Beyond the influence of IDH mutations: exploring epigenetic vulnerabilities in chondrosarcoma","volume":"12","author":"Venneker","year":"2020","journal-title":"Cancers (Basel)."},{"key":"10.1016\/j.ctrv.2026.103197_bb1205","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1056\/NEJMra1805035","article-title":"Epigenetic therapies for Cancer","volume":"383","author":"Bates","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ctrv.2026.103197_bb1210","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1038\/s41419-024-07007-8","article-title":"Phosphatase LHPP confers prostate cancer ferroptosis activation by modulating the AKT-SKP2-ACSL4 pathway","volume":"15","author":"Xie","year":"2024","journal-title":"Cell Death Dis"},{"key":"10.1016\/j.ctrv.2026.103197_bb1215","doi-asserted-by":"crossref","first-page":"2362","DOI":"10.1158\/1535-7163.MCT-21-0066","article-title":"Growth inhibition and induction of innate immune signaling of chondrosarcomas with epigenetic inhibitors","volume":"20","author":"Sheikh","year":"2021","journal-title":"Mol Cancer Ther"}],"container-title":["Cancer Treatment Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737226001118?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737226001118?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,6]],"date-time":"2026-09-06T22:28:33Z","timestamp":1788733713000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0305737226001118"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":243,"alternative-id":["S0305737226001118"],"URL":"https:\/\/doi.org\/10.1016\/j.ctrv.2026.103197","relation":{},"ISSN":["0305-7372"],"issn-type":[{"value":"0305-7372","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Chondrosarcoma: A comprehensive review of tumor biology, clinical behavior, and therapeutic advances","name":"articletitle","label":"Article Title"},{"value":"Cancer Treatment Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctrv.2026.103197","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"103197"}}